Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
96 shown of 6,700 total abstracts
  1. Abstract 103662026-06-01 · 19:15 CT · Hall B1
    KEYNOTE-974: Keytruda (pembrolizumab) 1L in metastatic melanoma
    C. Robert, M.C. Garassino, S. Peters, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  2. Abstract 103512026-06-01 · 13:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-261
    P. Schmid, S. Antonia, J. Cortes · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  3. Abstract 101192026-06-04 · 21:45 CT · E450
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-390
    L. Paz-Ares, M. Krop, G. Curigliano, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  4. Abstract 102832026-06-04 · 15:30 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    S. Peters, M. Reck, R. Herbst · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  5. Abstract 96922026-06-01 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-850
    M. Reck, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  6. Abstract LBA4005LBA2026-06-02 · 21:30 CT · Hall B1
    KEYNOTE-681: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Tolaney, H. Rugo, R. Herbst · Institut Gustave Roussy
    Plenary SessionMelanoma📄🖼️
  7. Abstract 96362026-06-05 · 20:45 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    R. Herbst, L. Paz-Ares · Stanford Cancer Institute
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  8. Abstract 98502026-06-04 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-36 study)
    M. Krop, M.C. Garassino · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  9. Abstract 98352026-06-01 · 14:45 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-709
    M. Krop, N. Rizvi, S. Antonia, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  10. Abstract 99262026-06-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-944 study)
    S. Modi, L. Paz-Ares, J. Cortes, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  11. Abstract 102532026-06-05 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-682 study)
    F. Andre, C. Robert, M. Reck, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  12. Abstract 101172026-06-02 · 21:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-203
    J. Brahmer, S. Modi · Princess Margaret Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  13. Abstract 96482026-06-05 · 13:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-918 study)
    S. Tolaney, C. Saura, R. Herbst, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  14. Abstract 101272026-06-04 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-203
    S. Peters, S. Tolaney, R. Herbst · MD Anderson Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  15. Abstract 98132026-06-02 · 21:00 CT · E450
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-434
    S. Tolaney, S. Antonia, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  16. Abstract 95122026-06-05 · 19:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-583
    L. Paz-Ares, E. Winer · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  17. Abstract 97942026-06-01 · 16:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-596 study)
    M. Krop, S. Tolaney, R. Herbst · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  18. Abstract 101382026-06-02 · 18:30 CT · E450
    CheckMate-284: Opdivo (nivolumab) adjuvant in metastatic melanoma
    C. Robert, S. Modi · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  19. Abstract 103252026-06-03 · 14:30 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    C. Saura, L. Paz-Ares, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  20. Abstract LBA4019LBA2026-06-04 · 15:45 CT · Hall B1
    CheckMate-504: Opdivo (nivolumab) adjuvant in metastatic melanoma
    S. Peters, M. Krop, P. Schmid · Massachusetts General Hospital
    Plenary SessionMelanoma📄🖼️
  21. Abstract LBA4020LBA2026-06-02 · 21:00 CT · E450
    KEYNOTE-905: Keytruda (pembrolizumab) 2L in metastatic melanoma
    M.C. Garassino, J. Brahmer, F. Andre, et al. · Mayo Clinic
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  22. Abstract LBA4021LBA2026-06-04 · 15:45 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    S. Antonia, L. Paz-Ares, F. Andre, et al. · Karolinska Institute
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  23. Abstract 102842026-06-04 · 19:45 CT · Hall B1
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-858
    S. Modi, P. Schmid · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  24. Abstract 97132026-06-01 · 14:15 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-365
    M. Reck, A. Spira, F. Andre, et al. · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  25. Abstract 96102026-06-01 · 13:30 CT · S100A
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-461
    S. Tolaney, L. Paz-Ares, A. Spira · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  26. Abstract TPS80252026-06-03 · 20:30 CT · S406
    CheckMate-327: Opdivo (nivolumab) adjuvant in metastatic melanoma
    R. Herbst, G. Curigliano, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionMelanoma📄🖼️
  27. Abstract 100962026-06-03 · 14:00 CT · S100A
    KEYNOTE-252: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    S. Peters, G. Curigliano, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  28. Abstract 102362026-06-01 · 20:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-315
    N. Rizvi, M. Krop · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  29. Abstract 97182026-06-04 · 21:30 CT · S406
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-868
    C. Saura, M. Reck, S. Antonia · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  30. Abstract 101832026-06-01 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-625
    T. Mok, S. Antonia, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  31. Abstract TPS80302026-06-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-814 study)
    F. Andre, P. Schmid, M.C. Garassino, et al. · University of Chicago
    Trials in Progress Poster SessionMelanoma📄🖼️
  32. Abstract 103462026-06-04 · 13:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-609
    S. Modi, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  33. Abstract 104372026-06-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-472 study)
    M. Krop, C. Robert, J. Brahmer, et al. · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  34. Abstract 95102026-06-05 · 16:30 CT · Hall B1
    CheckMate-28: Opdivo (nivolumab) 2L in metastatic melanoma
    J. Brahmer, A. Spira, S. Modi, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  35. Abstract LBA4034LBA2026-06-02 · 16:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-321
    L. Paz-Ares, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  36. Abstract 103592026-06-05 · 21:00 CT · S100A
    CheckMate-793: Opdivo (nivolumab) adjuvant in metastatic melanoma
    C. Robert, S. Tolaney, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  37. Abstract 100062026-06-05 · 14:30 CT · Hall B1
    KEYNOTE-109: Keytruda (pembrolizumab) 1L in metastatic melanoma
    M. Krop, S. Modi, C. Saura · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  38. Abstract 96672026-06-05 · 21:15 CT · S406
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-155
    M. Reck, L. Paz-Ares, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  39. Abstract TPS80382026-06-04 · 20:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-165
    S. Modi, L. Paz-Ares · Karolinska Institute
    Trials in Progress Poster SessionMelanoma📄🖼️
  40. Abstract 103092026-06-04 · 20:45 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-216
    T. Mok, C. Robert, H. Borghaei · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  41. Abstract e120402026-06-05 · 14:30 CT · S406
    CheckMate-367: Opdivo (nivolumab) 2L in metastatic melanoma
    J. Cortes, H. Rugo · Mayo Clinic
    Publication OnlyMelanoma📄🖼️
  42. Abstract 99112026-06-01 · 15:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-498
    F. Andre, G. Curigliano, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  43. Abstract 101012026-06-05 · 15:15 CT · E450
    CheckMate-941: Opdivo (nivolumab) maintenance in metastatic melanoma
    H. Borghaei, J. Cortes, H. Rugo, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  44. Abstract 102832026-06-01 · 16:45 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-744
    M. Reck, H. Rugo · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  45. Abstract 104792026-06-03 · 19:15 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-792
    J. Brahmer, M. Krop, H. Rugo, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  46. Abstract TPS80452026-06-04 · 20:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-216 study)
    H. Rugo, M. Krop, S. Peters · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionMelanoma📄🖼️
  47. Abstract 102782026-06-01 · 16:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-390 study)
    C. Robert, P. Schmid, S. Antonia, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  48. Abstract 100382026-06-05 · 16:00 CT · Arie Crown Theater
    KEYNOTE-278: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    N. Rizvi, F. Andre · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  49. Abstract 101022026-06-04 · 14:45 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-463
    T. Mok, E. Winer, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  50. Abstract 104312026-06-04 · 19:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-832
    M.C. Garassino, C. Saura, A. Spira · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  51. Abstract 98672026-06-04 · 15:15 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-800
    S. Tolaney, S. Peters, T. Mok, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumMelanoma📄🖼️
  52. Abstract 100272026-06-02 · 21:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-316
    S. Peters, F. Andre, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  53. Abstract 96282026-06-03 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-550
    H. Rugo, C. Saura, F. Andre · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  54. Abstract 100002026-06-01 · 20:00 CT · Arie Crown Theater
    CheckMate-257: Opdivo (nivolumab) maintenance in metastatic melanoma
    H. Borghaei, S. Antonia, J. Cortes · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  55. Abstract 100772026-06-01 · 19:45 CT · Hall B1
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-903
    A. Spira, H. Rugo · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  56. Abstract LBA4055LBA2026-06-01 · 16:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-780
    P. Schmid, H. Borghaei, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  57. Abstract 104252026-06-01 · 15:45 CT · S406
    CheckMate-735: Opdivo (nivolumab) adjuvant in metastatic melanoma
    H. Rugo, H. Borghaei, E. Winer, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  58. Abstract 103062026-06-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-866 study)
    J. Cortes, S. Modi, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  59. Abstract 96452026-06-03 · 15:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-154
    M. Reck, J. Brahmer, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  60. Abstract 103582026-06-02 · 18:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-722
    C. Saura, R. Herbst, L. Paz-Ares, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  61. Abstract 104132026-06-04 · 16:45 CT · Arie Crown Theater
    CheckMate-832: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    C. Robert, S. Tolaney, H. Borghaei, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  62. Abstract LBA4061LBA2026-06-05 · 19:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-780 study)
    S. Peters, S. Tolaney · Institut Gustave Roussy
    Plenary SessionMelanoma📄🖼️
  63. Abstract 97592026-06-04 · 13:15 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-583 study)
    H. Borghaei, M. Reck, C. Robert, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  64. Abstract 99882026-06-02 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-205
    M. Krop, S. Tolaney · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  65. Abstract 97902026-06-04 · 13:00 CT · E450
    KEYNOTE-45: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    J. Brahmer, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  66. Abstract 100262026-06-03 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-198
    M.C. Garassino, C. Robert, M. Reck · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  67. Abstract 101312026-06-01 · 18:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-410
    G. Curigliano, L. Paz-Ares, M. Reck, et al. · Cleveland Clinic
    Clinical Science SymposiumMelanoma📄🖼️
  68. Abstract 99202026-06-02 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-7 study)
    J. Cortes, R. Herbst, F. Andre, et al. · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  69. Abstract 98132026-06-05 · 19:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-740 study)
    L. Paz-Ares, M. Reck, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  70. Abstract 97142026-06-01 · 13:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-976
    J. Brahmer, R. Herbst · Cleveland Clinic
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  71. Abstract 98542026-06-04 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-364 study)
    S. Peters, F. Andre · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  72. Abstract 103602026-06-02 · 20:45 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-457 study)
    S. Peters, J. Cortes, F. Andre, et al. · Institut Gustave Roussy
    Clinical Science SymposiumMelanoma📄🖼️
  73. Abstract 97302026-06-02 · 16:45 CT · E450
    KEYNOTE-434: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Tolaney, H. Borghaei · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  74. Abstract 101102026-06-02 · 21:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-846
    C. Saura, J. Brahmer, M.C. Garassino · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  75. Abstract 104152026-06-04 · 19:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-604 study)
    M. Krop, L. Paz-Ares · Chinese University of Hong Kong
    Oral Abstract SessionMelanoma📄🖼️🎬
  76. Abstract 96382026-06-04 · 16:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-925 study)
    M.C. Garassino, S. Tolaney, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  77. Abstract 96032026-06-04 · 13:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-855
    J. Cortes, S. Antonia · Memorial Sloan Kettering Cancer Center
    Education SessionMelanoma📄🖼️
  78. Abstract 103832026-06-03 · 20:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-871
    S. Peters, S. Antonia · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  79. Abstract 104892026-06-04 · 16:15 CT · S100A
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-222
    S. Tolaney, H. Rugo · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  80. Abstract 97552026-06-05 · 20:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-33
    S. Tolaney, M.C. Garassino, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  81. Abstract TPS80802026-06-03 · 20:45 CT · E450
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-257
    R. Herbst, C. Saura · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionMelanoma📄🖼️
  82. Abstract 103322026-06-04 · 20:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-888 study)
    N. Rizvi, R. Herbst · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  83. Abstract 95202026-06-02 · 18:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-783 study)
    L. Paz-Ares, A. Spira, J. Brahmer, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  84. Abstract 95012026-06-03 · 19:30 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-137 study)
    M. Reck, J. Cortes, R. Herbst · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  85. Abstract 103252026-06-02 · 13:15 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-539
    C. Saura, S. Modi, F. Andre · University of Chicago
    Education SessionMelanoma📄🖼️
  86. Abstract 104492026-06-01 · 15:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-4
    C. Robert, F. Andre, S. Modi, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  87. Abstract 95732026-06-04 · 20:45 CT · S100A
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-53
    L. Paz-Ares, H. Borghaei · Dana-Farber Cancer Institute
    Clinical Science SymposiumMelanoma📄🖼️
  88. Abstract 97492026-06-03 · 14:45 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-278 study)
    A. Spira, S. Antonia, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  89. Abstract 100852026-06-03 · 21:00 CT · S406
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-780
    R. Herbst, N. Rizvi, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  90. Abstract 96212026-06-05 · 16:45 CT · S100A
    CheckMate-182: Opdivo (nivolumab) maintenance in metastatic melanoma
    S. Modi, N. Rizvi, S. Tolaney, et al. · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  91. Abstract 102222026-06-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-188 study)
    P. Schmid, G. Curigliano, F. Andre · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  92. Abstract 101712026-06-01 · 21:45 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-457
    R. Herbst, H. Borghaei · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  93. Abstract 98612026-06-01 · 21:15 CT · E450
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-476
    C. Robert, G. Curigliano, R. Herbst, et al. · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  94. Abstract 99752026-06-01 · 20:00 CT · E450
    CheckMate-350: Opdivo (nivolumab) 3L+ in metastatic melanoma
    S. Modi, E. Winer · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  95. Abstract LBA4094LBA2026-06-02 · 19:45 CT · S406
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-334
    S. Peters, E. Winer, J. Cortes, et al. · Karolinska Institute
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  96. Abstract 101422026-06-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-81 study)
    S. Antonia, C. Robert, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.